| CARLAT PUBLISHING

The FDA approved the use of Zubsolv on July 3. The medication contains buprenorphine and naloxone and is manufactured by Swedish drug maker Orexo AB. It comes in a once-daily tablet that dissolves under the tongue. Read More

FDA Rejects Implant Option

The FDA rejected a new medication to treat opioid addiction that would have been implanted under the skin. The implant, Probuphine, is a long-acting version of buprenophine that is implanted under the skin of the upper arm in a procedure that can be done in a physician’s office in about 10–15 minutes. Read More

Despite a large body of evidence providing overwhelming proof that misuse of cannabis can lead to the typical problems of substance abuse, some people continue to question the entire concept of cannabis (marijuana) addiction. Read More

While many people think marijuana is harmless, some people do become addicted to it. Roughly one million people receive substance abuse treatment for cannabis each year and the majority resume using marijuana following program discharge. Read More

Psychiatry Practice Boosters, Fourth Edition (2023)
Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
READ MORE

General Psychiatry
Using SAMe In Clinical Practice with Garrett Rossi, MD
Read More

Addiction Treatment
Supervised Drug Consumption Sites
Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.
Listen now